Search
Semaglutide Treatment Options in Tennessee
A collection of 64 research studies where Semaglutide is the interventional treatment. These studies are located in the Tennessee, United States. Semaglutide is used for conditions such as Diabetes Mellitus, Type 2, Obesity and Diabetes.
1 - 12 of 64
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Active Not Recruiting
Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries.
Participants will either get semaglutide or a dummy medicine - which treatment participants get is decided by chance.
Participants will need to inject themselves with medicine under the skin. Participants will need to do this once a week.
The study will last for about 5 years. Participants will have up to 21 clinic visits a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/18/2025
Locations: WR-ClinSearch, LLC, Chattanooga, Tennessee +3 locations
Conditions: Non-alcoholic Steatohepatitis
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Active Not Recruiting
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine togethe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Holston Medical Group Pc, Bristol, Tennessee +2 locations
Conditions: Type 2 Diabetes Mellitus
A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight
Completed
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance.
The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/15/2025
Locations: Holston Medical Group, Kingsport, Tennessee
Conditions: Overweight, Obesity, Type 2 Diabetes Mellitus
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Active Not Recruiting
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Gender:
ALL
Ages:
All
Trial Updated:
07/15/2025
Locations: Research Site, Bristol, Tennessee
Conditions: Diabetes Mellitus, Type 2
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
Active Not Recruiting
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested.
Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity.
The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. Th... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/14/2025
Locations: Pmg Research of Bristol, Bristol, Tennessee +3 locations
Conditions: Obesity
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
Completed
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.
The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to semaglutide.
Participants will either get IcoSema or semaglutide. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can alread... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: AM Diabetes And Endocrinology Center, Bartlett, Tennessee +1 locations
Conditions: Diabetes Mellitus, Type 2
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
Completed
This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone.
Before a new medicine can be prescribed to people it needs to be tested to see if it is safe and effective.
Participants will either get cagrilintide and semaglutide together or cagrilintide and a dummy medicine or semaglutide and a dummy medicine. Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Holston Medical Group, Kingsport, Tennessee
Conditions: Diabetes Mellitus, Type 2
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
Recruiting
The study is testing how well semaglutide can help adolescents with excess body weight to lose weight and to maintain weight loss. All participants in the study will receive semaglutide as a weekly injection. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. All participants will get semaglutide treatment for a minimum of 3 years.
Gender:
ALL
Ages:
Between 12 years and 15 years
Trial Updated:
07/02/2025
Locations: Clinical Neuroscience Solutions, Memphis, Tennessee
Conditions: Obesity
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
Active Not Recruiting
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines. If participants continue in the extension study, they will not receive any study medicine during the extension. The main study will look at how well CagriSema helps participants with excess body weight lose weight compared to a "dummy" medicine and 2 other medicines, cagrilintide and semaglutide. Participants will either get CagriSem... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/29/2025
Locations: Holston Medical Group_Bristol, Bristol, Tennessee +1 locations
Conditions: Obesity
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Recruiting
This study will look at how well CagriSema helps people with obesity lose weight compared to a "dummy medicine". CagriSema is a new medicine developed by Novo Nordisk. CagriSema cannot yet be prescribed by doctors. The study has two parts: First part is called the main phase and will last for 2 years, and second part is called the extension phase and will last for 1 year. In the main phase participants will either get CagriSema or "dummy medicine". Which treatment participants get is decided by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Holston Medical Group_Bristol, Bristol, Tennessee
Conditions: Obesity
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
Active Not Recruiting
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/24/2025
Locations: Genesis Neuroscience Clinic, Knoxville, Tennessee +1 locations
Conditions: Early Alzheimer's Disease
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
Active Not Recruiting
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.
Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.
The study will last for up to 173 weeks (about 3 years and 4 months). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10... Read More
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/24/2025
Locations: Genesis Neuroscience Clinic, Knoxville, Tennessee +1 locations
Conditions: Early Alzheimer´s Disease
1 - 12 of 64